Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.27, $0.06 worse than the analyst estimate of $0.33. Revenue for the quarter came in at $174.16 million versus the consensus estimate of $150.24 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.